

Special Issue

Recent Advances in Understanding Systemic Sclerosis

Message from the Guest Editor

Systemic sclerosis (SSc) is a complex, multifaceted autoimmune disease characterized by vascular abnormalities, immune system dysregulation, and progressive fibrosis of the skin and internal organs. Despite significant strides in understanding the pathogenesis of SSc, it remains a challenging condition to diagnose and manage due to its heterogeneity and its variability in clinical manifestations. The Special Issue “Recent Advances in Understanding Systemic Sclerosis” aims to highlight the latest research findings and clinical advancements in the field of SSc. Our goal is to provide a comprehensive overview of the current state of knowledge and to explore innovative therapeutic approaches that could improve patient outcomes. Topics within the scope of this Special Issue include, but are not limited to, the following:

- Diagnosis and assessment of SSc;
- Pathophysiology of SSc;
- The role of genetic and environmental factors in disease development;
- Cutting-edge insights into the molecular mechanisms underlying fibrosis;
- Novel and emerging therapies for SSc.

Guest Editor

Prof. Dr. Jörg Christoph Henes

Centre for Interdisciplinary Clinical Immunology, University of Tübingen,
72076 Tübingen, Germany

Deadline for manuscript submissions

closed (30 May 2025)



Sclerosis

an Open Access Journal
by MDPI



mdpi.com/si/206288

Sclerosis
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
sclerosis@mdpi.com

[mdpi.com/journal/
sclerosis](https://mdpi.com/journal/sclerosis)





Sclerosis

an Open Access Journal
by MDPI



[mdpi.com/journal/
sclerosis](https://mdpi.com/journal/sclerosis)



About the Journal

Message from the Editor-in-Chief

Welcome to *Sclerosis*.

Sclerosis is a term that encompasses various conditions that involve the stiffening and scarring of tissues and organs. It is a pathologic process of some highly prevalent diseases, such as multiple sclerosis, glomerulosclerosis, atherosclerosis, and more rare diseases, such as amyotrophic lateral sclerosis, systemic sclerosis, and tuberous sclerosis.

Sclerosis aims to provide a platform for dissemination of cutting-edge research and clinical practice in the field. Looking to similarities and differences among “sclerotic” diseases, we aim at identifying shared pathological mechanisms and risk factors, management pathways, and drugs with repurposing potential, while also exploring preventive and therapeutic strategies.

Editor-in-Chief

Dr. Maurizio A. Leone

1. Scientific Direction, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
2. Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 37.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.